Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients

Completed · Phase 3

Conditions studied: Prostate Cancer

In brief

The investigators are imaging patients with prostate cancer using a new Positron Emission Tomography (PET) imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detect prostate cancer.

Key facts

Study ID

NCT03803475

Run by

Thomas Hope

People needed

485

Starts

2018-10-11

Expected to finish

2020-08-25

Last updated by the study team

2021-08-24

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male, age >= 18.
• Histopathologically proven prostate adenocarcinoma.
• Concern for metastatic disease in one of the following settings:
• Initial staging with intermediate to high risk prostate cancer.
• Biochemical recurrence after initial therapy.
• Ability to understand a written informed consent document, and the willingness to sign it.

You may not qualify if…

• Patient unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.

Where it is running

• University of California, San Francisco — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.